A preparation method of a silicon-based phosphate ester includes the following steps: mixing a disilazane compound, a cyclic endoamine compound A and an organic base to carry out a pre-reaction, then adding an inorganic phosphate salt to carry out a mixing reaction to prepare the silicon-based phosphate ester. Types of the disilazane compound and cyclic endoamine compound are specifically defined. In the present application, the silicon-based phosphate ester is prepared by a reaction of the disilazane compound and the cyclic endoamine compound A with the organic base and the inorganic phosphate salt, and separation and purification of an intermediate are not required in the preparation process.

A battery including an anode, a cathode, a separator, and a liquid electrolyte including a lithium salt, a non-aqueous solvent, and an additive compound including a functionalized matrix having a polymer or copolymer or silica. The cathode material can be an NMC or LCO material. The electrode formed from the cathode or anode material can include a matrix additive. The matrix additive can be adhered to the separator or other inert component of the battery.

The present disclosure relates generally to certain compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions provided herein may be used for the treatment or prevention of a Retroviridae infection, including an HIV infection.

This application provides a secondary battery and a device comprising the same. The secondary battery includes a negative electrode plate and an electrolyte. The negative electrode plate includes a negative electrode active material. The electrolyte includes an electrolyte salt, an organic solvent, and an additive. The negative electrode active material includes a silicon-based material. The organic solvent includes ethylene carbonate (EC) and diethyl carbonate (DEC). A mass ratio of EC in the organic solvent is less than or equal to 20%, and a mass ratio of DEC in the organic solvent is less than or equal to 20%. The additive includes an additive A and an additive B. The additive A is selected from one or more of compounds represented by Formula 1 or Formula 2, and the additive B is selected from one or more of compounds represented by Formula 3, as described in the application.

Phospholipid compounds and methods of using the same, singly or in combination with additional agents, and pharmaceutical formulations of said compounds for the treatment of viral infections are disclosed.

The present invention provides a curable composition comprising one or more metal complex compounds comprising at least one metal from Groups 4 to 13, and a blocked isocyanate compound in which an isocyanate group of an isocyanate compound is blocked with a nitrogen-containing compound represented by the following Formula (1) or Formula (2).

Formula (1):

##STR00001## wherein R.sup.1, R.sup.2, R.sup.3, and R.sup.4 are as defined in the specification; or

Formula (2):

##STR00002## wherein R.sup.5, R.sup.6, and R.sup.7 are as defined in the specification.

A compound having a high molar absorption coefficient in a maximum absorption wavelength (max) within a range of 600 to 750 nm and good stability before and after post-baking when a color filter is produced.

The present invention relates to a compound represented by formula (I):

##STR00001## wherein Z.sup.1 and Z.sup.2 each independently represent a group represented by formula (i), R.sup.3 represents a hydrocarbon group optionally having a substituent, an aromatic heterocyclic group optionally having a substituent, or a group in which a hydrocarbon group optionally having a substituent and an aromatic heterocyclic group optionally having a substituent are combined, and CH.sub.2 contained in the hydrocarbon group is optionally replaced with O, CO, NR.sup.6, S, SO, or SO.sub.2,

##STR00002## wherein R.sup.7 represents a hydrogen atom, a hydrocarbon group optionally having a substituent, or a group represented by formula (ii), and a1 represents 0 or 1.

This disclosure relates to compounds and methods of using said compounds, as well as pharmaceutical compositions containing such compounds, for treating diseases and conditions mediated by TEAD, such as cancer.

The present disclosure relates generally to certain compounds, pharmaceutical compositions comprising said compounds, and methods of making and using said compounds and pharmaceutical compositions. The compounds and compositions provided herein may be used for the treatment or prevention of a Retroviridae infection, including an HIV infection.

The present invention pertains to the technical field of biomedicine, and relates to isopaucifloral F phosphate compounds and pharmaceutical uses thereof. It has been confirmed through experiments that said isopaucifloral F phosphate compounds and pharmaceutically acceptable salts thereof have effects on the bone remodeling process by exerting their anti-osteoporosis efficacy through a dual-mode mechanism of action of promoting osteogenesis and reducing osteoclast resorption, have the characteristics of high bioavailability, stable metabolism and good safety, and can be used to prepare a new generation of anti-osteoporosis drugs. ##STR00001##